Breast Cancer

Breast Cancer

Extended Letrozole Prolonged Survival in Postmenopausal Patients With Breast Cancer

When compared with the standard 2-3 years of letrozole, 5 years of letrozole treatment improved both disease-free survival and overall survival.

Cancer Therapy Advisor
Defer Surgery in Operable Breast Cancer: How Long is Too Long?

Researchers evaluate outcomes of surgery compared to PET in patients with non-advanced, operable invasive breast cancer to determine if PET as initial therapy may safely postpone surgery.

Breast Cancer
ESMO Clinical Practice Guideline for the Diagnosis, Staging and Treatment of Patients With Metastatic Breast Cancer

This ESMO Clinical Practice Guideline provides key recommendations and algorithms for managing metastatic breast cancer.

Annals of Oncology

Imaging Characteristics of Young Age Breast Cancer (YABC) Focusing on Pathologic Correlation and Disease Recurrence

Researchers investigate imaging characteristics of young age breast cancer focusing on correlation with pathologic factors and association with disease recurrence.

Scientific Reports
Chronic Stress Hard on Women With Breast Cancer

Physiologic "wear and tear" from lifelong exposure to stressors was associated with a decreased likelihood of completing chemotherapy and a lower overall survival in breast cancer patients. 

Multi-Omics Data Integration Reveals Correlated Regulatory Features of Triple Negative Breast Cancer

Research highlights the diversity of the different TNBC subtypes, and sharpens our understanding of the molecular pathways that govern this challenging breast cancer.

Molecular Omics
Comparison of Two-View versus Single-View Digital Breast Tomosynthesis and 2D-Mammography in Breast Cancer Surveillance Imaging

The aim of this study was to investigate the differences between two different DBT implementations in breast cancer surveillance imaging, for patients with a personal history of breast cancer.

Clustering Subtypes of Breast Cancer by Combining Immunohistochemistry Profiles and Metabolism Characteristics Measured Using FDG PET/CT

The aim of this study was to investigate the effect of combining immunohistochemical profiles and metabolic information to characterize breast cancer subtypes.

Cancer Imaging
Comprehensive Analysis of the Cancer Driver Genes in Breast Cancer Demonstrates Their Roles in Cancer Prognosis and Tumor Microenvironment

The purpose of this study was to identify the expression characteristics and prognostic value of cancer driver genes in breast cancer.

World Journal of Surgical Oncology
Drug-Drug Interactions Between Palbociclib and Proton Pump Inhibitors May Significantly Affect Clinical Outcome of Metastatic Breast Cancer Patients

Re et al question the effect of co-administration of PPIs and palbociclib on progression-free survival (PFS) in metastatic breast cancer (mBC) patients.

Assessment of Residual Cancer Burden and Event-Free Survival in Neoadjuvant Treatment for High-Risk Breast Cancer

Researchers study the pattern and prognosis for residual cancer burden after neoadjuvant chemotherapy in breast cancer patients. 

JAMA Oncology
Co-Expression and Prognosis Analyses of GLUT1–4 and RB1 in Breast Cancer

In this study, investigators analyze the co-expression of GLUT1–4 and the influence of GLUT1–4 gene expression on the prognosis of breast cancer.

BMC Cancer
Cost-Effectiveness of MR-Mammography in Breast Cancer Screening of Women With Extremely Dense Breasts After Two Rounds of Screening

This study evaluates the cost-effectiveness of MR-mammography vs. x-ray based mammography in two-yearly screening women of intermediate risk for breast cancer.

Frontiers in Oncology
Addition of Everolimus to Letrozole in Premenopausal Women With Advanced HR+, HER2- Breast Cancer

Fan et al find that the addition of everolimus to letrozole significantly improves PFS among premenopausal women with advanced HR+, HER2-breast cancer whose disease...

The ASCO Post
High-Risk Breast Cancer Screening in BRCA1/2 Carriers Leads to Early Detection and Improved Survival After a Breast Cancer Diagnosis

This study examines solid data on the effectiveness of high-risk screening of the BRCA1/2 carrier population in breast cancer.

Frontiers in Oncology
Does Radiotherapy Reduce the Long-Term Risk of Ipsilateral Breast Recurrence in Women With DCIS Who Underwent Lumpectomy?

Study investigators find that whole-breast irradiation vs observation is associated with reduced risk of all and invasive ipsilateral breast recurrence at 15 years in women undergoing lumpectomy...

The ASCO Post
Identification and Validation of a Five-Gene Signature Associated With Overall Survival in Breast Cancer Patients

This study investigates prognosis-related biomarkers in breast cancer. Gene expression profiles and clinical information of breast cancer patients were downloaded from the TCGA database. 

Frontiers in Oncology
Extended Follow-up of PALOMA-3 Supports Survival Benefit of Palbociclib Plus Fulvestrant in Advanced Breast Cancer

An updated analysis of this trial demonstrates continued superiority for the combination of palbociclib plus fulvestrant over fulvestrant plus placebo in women with HR+, HER2- advanced...

The ASCO Post
Meta-analysis of Outcomes With the Addition of Adjuvant Trastuzumab to Chemotherapy for HER2+ Breast Cancer

In a study reported in The Lancet Oncology, an individual patient data meta-analysis of randomized trials has shown that the addition of adjuvant trastuzumab to CT reduces the risk of...

The ASCO Post
Sacituzumab Govitecan-hziy Improves Survival vs Single-Agent Chemotherapy in Metastatic Triple-Negative Breast Cancer

The phase III ASCENT trial has shown prolonged PFS and OS with the Trop-2–directed antibody-drug conjugate sacituzumab govitecan-hziy vs single-agent CT in patients with R/R metastatic TNBC...

The ASCO Post
The Correlation Between Potential “Anti- Cancer” Trace Elements and the Risk of Breast Cancer

The main purpose of current study is to explore the differences of three potential “anti-cancer” trace elements selenium, molybdenum, and strontium between patients with malignant breast tumors...<

Frontiers in Oncology
Outcomes With 2 vs 5 Years of Hormone Therapy Following Adjuvant Endocrine Therapy in Postmenopausal Women With HR-Positive Breast Cancer

In a phase III trial, Dr Gnant and colleagues found no difference in DFS with 2 vs 5 years of treatment with the aromatase inhibitor anastrozole in postmenopausal women with...

The ASCO Post
Pyrotinib Plus Vinorelbine Versus Lapatinib Plus Capecitabine in Patients With Previously Treated HER2+ Metastatic Breast Cancer

Pyrotinib is a newly-developed irreversible pan-ErbB receptor oral tyrosine kinase inhibitor with promising efficacy in HER2+ breast cancer.

Frontiers in Oncology
HER2+ Breast Cancer & Neoadjuvant Checkpoint Inhibition

Adding the anti-PD-L1 antibody atezolizumab to standard neoadjuvant treatment (with chemotherapy plus dual HER2 blockade) in patients with high-risk HER2+ early breast cancer, did not improve pCR..

Oncology Times - Latest Articles
Circulating Tumor DNA to Interrogate the Safety of Letrozole-Associated Controlled Ovarian Stimulation for Fertility Preservation in Breast Cancer Patients

Study investigators assess the safety of let-COS in breast cancer patients using circulating tumor DNA as a surrogate biomarker of disease recurrence.

Frontiers in Oncology
How Many Years of Aromatase Inhibitor Tx in Breast Cancer?

How long is long enough―or too long―when it comes to adjuvant aromatase inhibitor therapy for postmenopausal women with early-stage HR+ breast cancer?

Risk of Breast Cancer in Women Older Than Age 65 With Germline Pathogenic Variants in Predisposition Genes

In this study, investigators find that women older than age 65 in the general population who carry germline pathogenic variants in established high-risk breast cancer predisposition genes remain...

The ASCO Post
Predictors for Fear of Cancer Recurrence in Breast Cancer Patients Referred to Radiation Therapy During the COVID-19 Pandemic

The outbreak of COVID-19 pandemic has greatly impacted on RT strategy for breast cancer patients, which might lead to increased distressing psychological symptoms.

Frontiers in Oncology
Breast-Conserving Surgery Plus Radiotherapy May Yield Better Survival Than Mastectomy With or Without Radiotherapy

de Boniface et al find that breast-conserving surgery plus RT for women with breast cancer is associated with better survival vs mastectomy with or without RT in analysis adjusting for...

The ASCO Post
Real-World Survival Outcomes With Pertuzumab Plus T-DM1 for HER2-Positive Metastatic Breast Cancer

Study investigators identify real-world survival outcomes among women receiving pertuzumab and trastuzumab emtansine for stage IV HER2+ breast cancer...

The ASCO Post
Pyrotinib in the Treatment of Women With HER2-Positive Advanced Breast Cancer

This multicenter study analyzes the real-world data of women treated with pyrotinib-based therapy, aiming to describe their characteristics, treatment regimens, and to investigate...

Frontiers in Oncology
Effect of Celecoxib vs Placebo as Adjuvant Therapy on DFS Among Patients With Breast Cancer

This study examines if there is a benefit for patients who receive celecoxib as an addition to conventional therapy for women with ERBB2 (formerly HER2)–negative primary breast cancer.

JAMA Oncology
Identification of a Three-RNA Binding Proteins Signature Predicting Prognosis for Breast Cancer

In this study, investigators focused on the communal differently expressed RBPs in four subtypes of breast cancer.

Frontiers in Oncology

source list reference

rgb(171, 222, 222)
200, 66, 245
rgb(195, 2, 230)
rgb(209, 15, 15)
rgb(115, 43, 196)
rgb(9, 151, 227)
rgb(242, 0, 137)
rgb(48, 38, 189)
rgb(231, 165, 240)
rgb(230, 21, 49)
rgb(156, 242, 7)
rgb(224, 4, 129)
rgb(80, 147, 199)
rgb(5, 235, 235)
rgb(235, 190, 9)
rgb(209, 227, 11)
200, 66, 245
rgb(217, 7, 192)
rgb(2, 230, 230)